Once-Daily Oral Dose of BeneFlax to Healthy Older Adults
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 2
- 主要终点
- Safety of consumption of 600 mg/day of the flax lignan secoisolariciresinol diglucoside (SDG) in older adults (60-80 y)
研究概览
简要总结
The investigators are investigating whether the flax lignan, secoisolariciresinol diglucoside, decreases oxidative stress and inflammation. The flax seed lignan is believed to be broken down in the body to produce the health benefits of flax. Flax lignan is separated from the whole flax seed as this compound is believed to have health effects. Decreasing oxidative stress and inflammation should improve a number of the problems associated with aging. This intervention consists of 600 milligrams of the flax lignan SDG daily or an equivalent amount of whey protein.
The investigators are comparing lignan to a placebo (whey powder) to examine whether a dietary intervention (i.e. flax seed containing lignan) might decrease oxidative stress and inflammation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 60 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female adult 60 to 80 years residing in Saskatoon.
- •Able to comply with study protocol.
- •Able to follow simple instructions.
排除标准
- •Age below 60 or above 80 years at initiation of the study.
- •Individuals living in long term care homes.
- •Individuals at risk of hypotension or with symptomatic hypotension.
- •Fasting hypoglycemia.
- •Unstable diabetes, or diabetics taking insulin (note: eligible diabetic participants will undergo additional testing during the study).
- •Current cancer or diagnosed with cancer in the past 2 years.
- •Women with an immediate family history or personal history of breast cancer or ovarian cancer.
- •Significant liver or other gastrointestinal disorder including inflammatory bowel disease. (While constipation is the most common gastrointestinal problem in the elderly, it would not be a contraindication)
- •Significant kidney disorder.
- •Unstable or severe cardiac disease, recent myocardial infarction or stroke (either in past 6 months or significantly affecting physical mobility).
- •Unstable other medical disease including, but not limited to, pulmonary disorder, epilepsy and genitourinary disorder.
- •Migraine with aura within the last year (as this is a risk factor for stroke).
- •Current diagnosis of a bleeding condition, or at risk of bleeding.
- •Significant immunocompromise.
- •Other unstable conditions.
- •Current use of hormone replacement therapy (except thyroid medication is allowed).
- •Current use of warfarin, clopidogrel, ticlopidine, dipyridamole or their analogues.
- •Intolerances or allergies to flax or vitamin D.
- •Allergy to whey
- •Surgery within the last six months.
- •Participation in any other clinical trial with an investigational agent within one month prior to randomization.
研究组 & 干预措施
secoisolariciresinol diglucoside
Secoisolariciresinol diglucoside (SDG) supplementation as 1.6g/day of BeneFlax containing 600 mg SDG. 1000 IU vitamin D as standard of care.
干预措施: secoisolariciresinol diglucoside, vitamin D (Dietary Supplement)
Whey powder
Natural Factors Whey Factors whey protein (unflavored). An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
干预措施: secoisolariciresinol diglucoside, vitamin D (Dietary Supplement)
结局指标
主要结局
Safety of consumption of 600 mg/day of the flax lignan secoisolariciresinol diglucoside (SDG) in older adults (60-80 y)
时间窗: 24 weeks
Adverse event occurrences will be compared descriptively between the SDG and placebo groups. Safety will be assessed at 0, 8, 16 and 24 weeks; as part of the blood collection (urea, creatinine, total bilirubin, platelets, hematocrit, haemoglobin, mean corpuscular haemoglobin, mean corpuscular volume, white blood cell count, total protein including albumin and prealbumin, total calcium, electrolytes, glucose, liver enzymes (Aspartate transaminase (AST), Alanine Aminotransferase (ALT), Alkaline phosphatase (ALP), total protein, albumin, lipids, HbA1c (for diabetic participants). Blood pressure, pulse and respiratory rate will also be monitored at these time points.
次要结局
- Effect of SDG on inflammation(24 weeks)
- Effect of SDG on quality of life(24 weeks)
- Effect of SDG on blood lipids(24 weeks)
- Effect of SDG supplement on blood levels of flax lignan metabolites(24 weeks)
- Effect of SDG supplement on fecal levels of flax lignan metabolites(24 weeks)